Klow · 80mg
Research blendGLOW + KPV (10 mg) · repair and skin with an extra brake on inflammation, in gut and skin
Overview
What has it been researched for?
- Closes wounds and ulcers Main focusEarly evidence
- Lowers inflammationEarly evidence
- Calms reactive, irritated skinEarly evidence
- Repairs tendon, ligament and muscleEarly evidence
- Calms gut inflammationEarly evidence
- Firmer, denser skin: more collagenEarly evidence
Research protocols
The SBL research protocol and what the literature reports. Not medical advice.
SBL research protocol · no established clinical regimen in people
- Dose
- 1.6 → 3.2 mg
- Frequency
- diario · noche
- Duration
- 12 weeks
- Route
- Subcutaneous
- Evidence level
- Extrapolated
Tools
Evidence and studies
See studies →Protocols
Research protocols
SBL research protocol · no established clinical regimen in people
Research use, with no established clinical regimen in people.
- Dose
- 1.6 → 3.2 mg
- Frequency
- diario · noche
- Timing
- noche
- Duration
- 12 weeks
- Break
- 3 weeks
- Route
- Subcutaneous
- Evidence level
- Extrapolated
Example dose
30-unit U-100 insulin syringe · Starting dose of its protocol, with 3 ml of water in the 80 mg vial.
What it pairs with
Preparation and dosing
Quick reference
Preparation
- Diluent
- Bacteriostatic water
Evidence
Each effect with its evidence level and, where available, its source.
- Closes wounds and ulcersExtrapolatedSee study · 1994
- Lowers inflammationPreclinicalSee study · 2007
- Calms reactive, irritated skinPreclinicalSee study · 2004
- Repairs tendon, ligament and musclePreclinicalSee study · 2026
- Calms gut inflammationPreclinicalSee study · 2008
- Firmer, denser skin: more collagenExtrapolatedSee study · 2015
The science
Mechanisms, studies and references
GHK + KPV + BPC + TB
Safety
It makes sense if you want
- Skin healing & regeneration
- General body recovery
- Recover from an injury (tendon, joint)
It does not make sense if
- Active cancer or oncology treatment in the last 5 years
- Pregnancy or breastfeeding
- Wilson disease or copper allergy
- Severe liver impairment
Talk to your doctor first if this applies (2)
- Anticoagulants (warfarin, rivaroxaban, etc.)
- Immunosuppressants
The certificate of analysis (CoA) certifies the identity and purity of the batch. It does not certify safety of use.
Verify your batch →For research use only (RUO). This consult is educational and does not replace your doctor.
Questions
Frequently asked questions
What is it reconstituted with, and how much?
With bacteriostatic water: 3 ml into the 80 mg vial, giving 26.67 mg/ml.
What is the starting dose of the research protocol?
1.6 → 3.2 mg, diario · noche. This is the SBL research protocol, with no established clinical regimen in people.
How long is the cycle, and how long does a vial last?
12 weeks ON / 3 weeks OFF. At the starting dose, the 80 mg vial lasts ~4 sem.
Which route is used in research?
Subcutaneous.
When does it make no sense?
It makes no sense with: Active cancer or oncology treatment in the last 5 years, Pregnancy or breastfeeding, Wilson disease or copper allergy, Severe liver impairment. Details in the Safety tab.
How do I check my batch?
With the code on the vial, in the verifier. The CoA certifies the identity and purity of the batch, not safety of use.
For research use only (RUO). This consult is educational and does not replace your doctor.